← All organizations
Highest phase reached
Phase 3
Last known activity
Jan 29, 2013
Defunct as of May 1, 2018
Timeline
2010s
- Jan 29, 2013
mipomersen— NDA Secondary Org
- Jan 1, 2015
Kastle Therapeutics, LLC— Founded
- May 1, 2018
Kastle Therapeutics, LLC— Defunct
Drugs by trial phase (3 distinct, 18 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Congenital Abnormalities
- Coronary Artery Disease
- Coronary Disease
- Disease
- Dyslipidemias
- Genetic Diseases, Inborn
- Heart Diseases
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperlipoproteinemia Type II
- Hypobetalipoproteinemias
- Hypolipoproteinemias
- Infant, Newborn, Diseases
- Lipid Metabolism Disorders
- Lipid Metabolism, Inborn Errors
- Metabolic Diseases
- Metabolism, Inborn Errors
- Myocardial Ischemia
Marketed drugs (1)
Recent trials (18)
- NCT01475825Lead sponsorPhase 3Dec 1, 2011
- NCT01414881Lead sponsorPhase 1Sep 1, 2011
- NCT01299298Lead sponsorPhase 1Jan 1, 2011
- NCT01133366Lead sponsorPhase 1May 1, 2010
- NCT01090661Lead sponsorPhase 1Mar 1, 2010
- NCT01061814Lead sponsorPhase 1Jan 1, 2010
- NCT00794664Lead sponsorPhase 3Jan 1, 2009
- NCT00770146Lead sponsorPhase 3Nov 1, 2008
- NCT00707746Lead sponsorPhase 2Oct 1, 2008
- NCT00706849Lead sponsorPhase 3Jul 1, 2008
- NCT00694109Lead sponsorPhase 3Apr 1, 2008
- NCT00607373Lead sponsorPhase 3Jul 1, 2007
- NCT00477594Lead sponsorPhase 2May 1, 2007
- NCT00362180Lead sponsorPhase 2Jul 1, 2006
- NCT00281008Lead sponsorPhase 2Feb 1, 2006
Details
- Founded
- Chicago, IL, US Jan 1, 2015
- Last known activity
- Jan 29, 2013